Full Press Release Details
Alpha Tau Announces Multiple Corporate Updates
Ahead of 2022 Annual Meeting of the American Society for Radiation Oncology
- Medicines and Healthcare products Regulatory Agency of the United
Kingdom approves clinical trial in squamous cell carcinoma of the vulva at Addenbrookes Hospital in Cambridge -
- Health Canada approves the addition of Jewish General Hospital
in Montreal as a second site in the Company's clinical trial in advanced pancreatic cancer -
- Dr. Christopher Barker of Memorial Sloan Kettering Cancer
Center will be delivering a presentation at the ASTRO 2022 Annual Meeting regarding results of the Company's U.S. pilot feasibility
study completed earlier in 2022 -
- Investigators at The University of Texas MD Anderson Cancer Center
presented a poster at the Radiation Research Society's 2022 Annual Meeting on tumor growth delay and immune stimulation using the
Alpha DaRT in treating 4T1 murine triple-negative breast cancer tumors -
October 21, 2022 - Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company"), the developer of the innovative
alpha-radiation cancer therapy Alpha DaRT , announced today its participation in the upcoming 2022 Annual Meeting of the American
Society for Radiation Oncology ("ASTRO"), being held October 23 - 25, 2022 in San Antonio, TX, where the Company
will be at Booth #3719. Participants interested in meeting with the Alpha Tau team at the conference can do so by booking a slot via
the following link: https://calendly.com/michaelt-alpha-dart/. Ahead of the conference, the Company is pleased to announce
a number of recent developments:
Alpha Tau CEO Uzi Sofer commented, "Following
the completion of our U.S. pilot study earlier this year, we are laser-focused on initiating our U.S. multi-center pivotal study for the
treatment of recurrent cutaneous Squamous Cell Carcinoma using the Alpha DaRT, which we expect to occur before the end of the year, as
we are currently progressing on the associated preparatory logistics such as IRB approvals and site initiations. At the same time, we
continue to forge ahead in our strategy to broaden the application of the Alpha DaRT to other indications, and are very excited to see
continued meaningful progress across three different indications: cancer of the vulva, pancreas and breast. We look forward to further
advances in these and other indications, as we continue to explore ways that the Alpha DaRT can help patients around the world."
Alpha DaRT (Diffusing Alpha-emitters
Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224
impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy
alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to
mainly affect the tumor, and to spare the healthy tissue around it.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that
focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology
was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
Forward-Looking Statements
This press release includes "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including "anticipate,"
"being," "will," "plan," "may," "continue," and similar expressions are intended to
identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections,
objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.
All forward-looking statements are based upon Alpha Tau's current expectations and various assumptions. Alpha Tau believes there is a
reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and
its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements
as a result of various important factors, including, without limitation: (i) Alpha Tau's ability to receive regulatory approval for
its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau's limited operating history; (iii) Alpha
Tau's incurrence of significant losses to date; (iv) Alpha Tau's need for additional funding and ability to raise capital when needed;
(v) Alpha Tau's limited experience in medical device discovery and development; (vi) Alpha Tau's dependence on the success and
commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau's clinical studies to predict
final study results; (viii) failure of Alpha Tau's early clinical studies or preclinical studies to predict future clinical studies;
(ix) Alpha Tau's ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau's Alpha
DaRT technology or any future products or product candidates; (xi) Alpha Tau's exposure to patent infringement lawsuits; (xii) Alpha
Tau's ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq's listing standards; (xiv) costs
related to being a public company; (xv) changes in applicable laws or regulations; (xix) impacts from the COVID-19 pandemic;
and the other important factors discussed under the caption "Risk Factors" in Alpha Tau's annual report filed on form 20-F with
the SEC on March 28, 2022, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These
and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made
in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While
Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any
obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as
representing Alpha Tau's views as of any date subsequent to the date of this press release.
Investor Relations Contact